Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men.
We sought to assess trends in prostate cancer incidence, treatment and mortality in African American men by means of analysis of prostate cancer data from three states, Connecticut, Iowa and New Mexico, all participants in the Surveillance, Epidemiology, and End Results (SEER) Program. Compared with levels before prostate specific antigen (PSA) testing, prostate cancer incidence increased in all three states after widespread testing. For men diagnosed with localized or regional prostate cancer, the respective increases in radical prostatectomy in Connecticut, Iowa, and New Mexico were 3.2, 2.3, and 4.9 times pre-test levels. Age-standardized mortality in Connecticut and Iowa increased slightly; in New Mexico the 104.7 deaths per 100,000 in 1979-1986, 62.1 in 1987-1990, dropped to 47.6 in 1991-1998, an amount of decline that was statistically significant. Introduction of PSA testing influenced early detection and treatment of prostate cancer in all three states. Although decline in prostate cancer mortality in New Mexico over time may be linked with use of the PSA test and definitive therapy, the relationship among these factors, and thus the proper treatment for the early stages of this condition, is unclear on the basis of these data.
Escobedo
Luis G
LG
Public Health Division, New Mexico Department of Health, 1170 North Solano, Suite L, Las Cruces, NM 88001, USA. luise@doh.state.nm.us
Rivas
Saul D
SD
Holmes
Michelle D
MD
D001741:Black or African American / Q000706:statistics & numerical data*; D000368:Aged; D003237:Connecticut / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007484:Iowa / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009516:New Mexico / Q000453:epidemiology; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000208:ethnology / Q000401:mortality*; D015996:Survival Rate / Q000639:trends
D017430:Prostate-Specific Antigen